Canaccord Genuity Issues Top 5 Diagnostics Picks for 2018
Canaccord Genuity's diagnostics analyst Mark Massaro has released his own top picks for 2018. These top five picks in the space have a combined market cap of over $70 billion.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 147
Why Eiger BioPharma Shares Are Getting Crushed
Eiger BioPharmaceuticals watched its shares crater on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension did not meet its primary endpoint.
Merck Wins Big With Late-Stage Lung Cancer Drug Results
Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met its dual primary endpoints.
How the New Tax Law Boosted UnitedHealth Earnings and Forecast
UnitedHealth reported fourth-quarter and full-year results Tuesday morning that beat analysts estimates. The company also raised guidance for 2018 based on the impact of the new tax law.
What to Expect From UnitedHealth Group Earnings
UnitedHealth Group reports fourth-quarter and full-year 2017 earnings Tuesday morning before the markets open. Analysts are expecting another solid performance by the company with more to come following recent changes to the tax law.
Meet the Top Biotech Movers of This Past Week
Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Here are a few of the standouts from the past week.
Short Sellers Grow More Selective on Major Biotechs
The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Major Pharma Short Interest Takes a Plunge
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Why Alder Biopharma Is Winning Big on Monday
Alder Biopharmaceuticals saw its shares make a solid gain on Monday amid a blizzard of updates from the company.
Axovant Crumbles Following Alzheimer’s Study Update
Axovant Sciences watched its shares practically get halved in Monday’s session after the firm provided an update from a few of its midstage clinical trials.
20 More Biopharma Catalysts Coming in 2018
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Is the World Health Organization Kicking Older People to the Curb?
The World Health Organization does not refer to the illnesses and conditions of people older than 60 in its draft program of work for the period 2019 to 2023. Is that an oversight or…
Investors Cheer Secondary Offering for Gene-Editing Firm
While most secondary offerings would bring down the price of the stock, this case is different and shareholders are cheering this dilution because it might bring about something greater.
Meet Merrill Lynch’s Top Biotech Picks for 2018
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Audentes Therapeutics Pulls Off Positive Interim Results
Audentes Therapeutics shares made a handy gain on Thursday after the company announced positive interim data for a midstage trial.